) third-quarter 2013 core earnings of $1.21 per American
Depositary Share (ADS) missed the Zacks Consensus Estimate of
$1.28. Earnings were also down 26% (at constant exchange rates or
CER) year over year.
ASTRAZENECA PLC (AZN): Free Stock Analysis
BAYER A G -ADR (BAYRY): Free Stock Analysis
JOHNSON & JOHNS (JNJ): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
To read this article on Zacks.com click here.
AstraZeneca's quarterly revenues fell 4% (at CER) year over year
to $6.3 billion, primarily due to intense generic competition.
Revenues were below the Zacks Consensus Estimate of $6.5 billion.
The adverse effect of the genericization of products, which
recently lost patent protection, was approximately $350 million.
All growth rates mentioned below are on a year-on-year basis and
The Quarter in Detail
U.S. revenues were down 8% in the third quarter to $2.4 billion,
primarily due to generic competition and inventory destocking
(Crestor and Nexium). Additionally, U.S. healthcare reforms
impacted revenues and costs by $199 million.
Revenues declined 2% in Rest of the World (RoW) to $3.9 billion.
The decline was attributed to weakness in the European markets,
which were down 4% primarily due to generic erosion of Seroquel
IR, Seroquel XR, Atacand and Nexium.
Established RoW revenues were down 8%. Results were hurt by weak
Crestor sales in Canada (42%) and Australia (68%) and Nexium in
Canada due to generic competition. Revenues in Emerging Markets
witnessed 5% growth in the reported quarter. China (up 13%)
experienced slower growth due to inventory destocking.
Drugs facing generic competition include Seroquel IR (down 47% to
$84 million), Seroquel XR (down 10% to $339 million), Arimidex
(down 26% to $90 million), Casodex (down 5% to $93 million),
Atacand (down 35% to $143 million), Losec/Prilosec (down 34% to
$118 million), Nexium (down 5% to $918 million), Crestor (down
11% to $1.4 billion), Seloken/Toprol-XL (down 23% to $173
million) and Merrem (down 23% to $67 million).
However, drugs such as Iressa (up 12% to $165 million), Onglyza
(up 10% to $93 million), Symbicort (up 7% to $839 million),
FluMist (up 30% to $188 million), Synagis (up 35% to $130
million) and Faslodex (up 3% to $169 million) performed well
during the quarter.
Newly launched Brilinta sales were $75 million in the third
quarter of 2013 compared with $65 million in the preceding
quarter. Other newly launched products including Bydureon,
Forxiga and Vimovo contributed $43 million, $3 million and $23
million, respectively to total revenues during the quarter.
AstraZeneca's core gross margin decreased 120 basis points to
82.4% in the third quarter of 2013. Core selling, general and
administrative (SG&A) expenses went up 11% to $2.2 billion,
primarily due to investments in Emerging Markets, Brilinta and
the diabetes franchise.
During the quarter, core research and development (R&D)
expenses amounted to $1.1 billion, reflecting an increase of 7%.
Investments in pipeline were partially offset by savings from
AstraZeneca continues to expect 2013 revenue to decline in
mid-to-high single digits and core earnings to decline
considerably more than revenues. For 2013, the company expects a
high single-digit growth rate in Emerging Markets.
Generic competition has adversely impacted AstraZeneca's revenues
over the past few quarters. This has put significant pressure on
the company. AstraZeneca is looking toward cost-cutting
initiatives to drive the bottom line in the face of
The company expects to boost its pipeline by acquiring
candidates. As a result, core operating costs are now expected to
increase in the upper end of low-to-mid, single-digit range
(previous guidance: low-to-mid, single-digit increase).
In a bid to bolster its pipeline, AstraZeneca made several
acquisitions (Spirogen, Amplimmune, Pearl Therapeutics and
Omthera Pharmaceuticals) in the last few months and forged
agreements with companies such as
Merck & Co. Inc.
), ADC Therapeutics,
Johnson & Johnson
) and FibroGen, Inc.
AstraZeneca, a large cap biopharmaceutical company, currently
carries a Zacks Rank #3 (Hold). However, large cap pharma stock
like Johnson & Johnson and
), currently look better-positioned with a Zacks Rank #2